A Phase 2/3 interventional study of BYM338 (Bimagrumab) in Sporadic Inclusion Body Myositis (sIBM), sponsored by Novartis Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 2/3, and was the 19th registered.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Myositis International Health & Research Collaborative Alliance Foundation · Sites in United States
Ages 7+
Austin Neuromuscular Center · Sites in United States
Ages 45–75
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 2–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 9
First in 1990; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Median enrollment 24 across the 27 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 6 studies filed under Myositis, Inclusion Body — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis, Inclusion Body with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05046821University of California, IrvineSporadic Inclusion Body Myositis Natural History Study | 2027-03-31 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg i.v. dose of BYM338. This study is designed to confirm the efficacy, safety and tolerability of BYM338 in sIBM with long-term dosing. However due to lack of efficacy in patients with sIBM, the study was terminated early.
This is a non-confirmatory, multicenter, open-label, non-randomized trial which will extend active treatment to those patients that participated in the preceding proof-of-concept study (CBYM338X2205) in order to collect long-term safety and tolerability data. Up to 14 patients with sIBM will be invited to enroll into the study to receive BYM338 open-label for a period of approximately 3 years or until BYM338 is commercially available, whichever comes first. The study consists of a maximum 28-day screening period, a 5-day baseline period, and a treatment period consisting of the site visits at 4-week intervals for treatment administration, safety and pharmacokinetic follow-up. All patients will be administered a medium level i.v. BYM338 dose regardless of their treatment allocation in the prior study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of , defined as all women physiologically capable of becoming pregnant, must use highly effective during the study and for 5 half-lives (14 weeks) after stopping treatment. Highly effective contraception is defined as either:
<!-- -->
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by a plasma FSH level of > 40 IU/L (or as determined by the cut off used by the local clinical laboratory) at screening. Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the eCRF. All female patients must have negative pregnancy test results at screening and baseline.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BYM338 Group
Drug: BYM338 (Bimagrumab)
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity
Time frame: Up to 29 month
Changes From Baseline in Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA)
To assess the effect of multiple doses of BYM338 on lean body mass as measured by DXA in terms of change from baseline.
Time frame: Baseline, Day 1, 57, 113, 169, 365, 533, and day 729
Pharmacokinetics (PK) Parameter of Cmin From Multiple i.v. Dosing
To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1. Pre-dose only on each subsequent administration
Time frame: Day 29, 85, 169, 253, 337, 421, 505, 589, 673, 757, 1177
Changes From Baseline in Physical Function Reported by Patients
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. Due to the no-signal this analysis was cancelled.
Time frame: Baseline, Week 104
Changes From Baseline in Muscle Strength.
Quadriceps muscle strength was measured, Quadriceps Quantitative Muscle Testing (QMT) by portable fixed dynamometry (PFD). A negative change from baseline indicates deterioration
Time frame: Baseline, Day 1, 113, 169, 365, 533, 729
Changes From Baseline in Muscle Function (Hand-grip and Pinch-grip Dynamometry)
The effect of BYM338 on additional muscle function measures (hand-grip and pinch-grip dynamometry).
Time frame: Baseline,Day 1, 113, 169, 365, 533, 729
Changes From Baseline in Muscle Function 6 Minute Walking Distance
The effect of BYM338 on additional muscle function measures (6 minute walking distance). The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.
Time frame: Baseline,Day 1, 113, 169, 365, 533, 729
Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was equal or more than 2% at Week 8 and 16 were considered responders
Time frame: Baseline, Day 1, 57, 113
Pharmacokinetics (PK) Parameter of Cmax
To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1.
Time frame: Day 1
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
The time to reach the maximum concentration after drug administration
Time frame: Day 1
Due to lack of efficacy in patients with sIBM, the study was terminated early.
| Milestone | BYM338 |
|---|---|
| Started | 10 |
| Completed | 0 |
| Not completed | 10 |
| Withdrew: Administrative problems | 7 |
| Withdrew: Adverse event | 3 |
Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity
| Participants | BYM338 |
|---|---|
| Death | 0 |
| Serious adverse events (SAE) | 2 |
| Adverse Events (AE) | 10 |
To assess the effect of multiple doses of BYM338 on lean body mass as measured by DXA in terms of change from baseline.
| Percentage Change in LBM | BYM338 |
|---|---|
| Day 1 | 0 ± 0 |
| Day 57 | 4.292 ± 2.7480 |
| Day 113 | 5.552 ± 3.6066 |
| Day 169 | 7.463 ± 4.5687 |
| Day 365 | 6.919 ± 2.9669 |
| Day 533 | 6.885 ± 3.7894 |
| Day 729 | 0.727 ± NA |
To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1. Pre-dose only on each subsequent administration
| ng/mL | BYM338 |
|---|---|
| Day 29 (n=10) | 13.4 ± 5.01 |
| Day 85 (n=10) | 24.1 ± 13.1 |
| Day 169 (n=10) | 26.3 ± 15.9 |
| Day 253 (n=9) | 28.8 ± 12.1 |
| Day 337 (n=10) | 24.4 ± 14.6 |
| Day 421 (n=9) | 24.5 ± 11.5 |
| Day 505 (n=8) | 28.3 ± 10.6 |
| Day 589 (n=6) | 39.8 ± 30.2 |
| Day 673 (n=2) | 20.5 ± 1.98 |
| Day 757 (n=1) | 20.3 ± NA |
| Day 1177 (n=1) | 31.4 ± NA |
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. Due to the no-signal this analysis was cancelled.
No measurements were reported for this outcome.
Quadriceps muscle strength was measured, Quadriceps Quantitative Muscle Testing (QMT) by portable fixed dynamometry (PFD). A negative change from baseline indicates deterioration
| Newtons | BYM338 |
|---|---|
| Quadriceps score left side Day 1 | 0 ± 0 |
| left side Day 113 | -5.80 ± 28.160 |
| left side Day 169 | -5.95 ± 26.587 |
| left side Day 365 | -9.51 ± 28.149 |
| left side Day 533 | -25.77 ± 21.321 |
| left side Day 729 | 178.26 ± NA |
| Quadriceps score Right side Day 1 | 0 ± 0 |
| Right side Day 113 | -4.83 ± 29.904 |
| Right side Day 169 | -22.81 ± 18.784 |
| Right side Day 365 | -11.63 ± 47.141 |
| Right side Day 533 | -31.00 ± 29.173 |
| Right side Day 729 | -57.66 ± NA |
The effect of BYM338 on additional muscle function measures (hand-grip and pinch-grip dynamometry).
| Newtons | BYM338 |
|---|---|
| Left hand-grip day 1 | 0 ± 0 |
| Left hand-grip day 113 | 25.58 ± 37.544 |
| Left hand-grip day 169 | 21.36 ± 43.815 |
| Left hand-grip day 365 | -1.42 ± 47.973 |
| Left hand-grip day 533 | 2.78 ± 16.934 |
| Left hand-grip day 729 | 8.95 ± 24.034 |
| Right hand-grip day 1 | 0 ± 0 |
| Right hand-grip day 113 | 99.59 ± 184.472 |
| Right hand-grip day 169 | 109.05 ± 214.248 |
| Right hand-grip day 365 | 77.46 ± 160.133 |
| Right hand-grip day 533 | 53.99 ± 127.776 |
| Right hand-grip day 729 | 163.66 ± 237.402 |
| Left hand pinch grip day 1 | 0 ± 0 |
| Left hand pinch grip day 113 | 7.82 ± 27.292 |
| Left hand pinch grip day 169 | -4.74 ± 20.210 |
| Left hand pinch grip day 365 | -7.30 ± 35.224 |
| Left hand pinch grip day 533 | -11.40 ± 21.204 |
| Left hand pinch grip day 729 | -8.41 ± 46.672 |
| Right hand pinch grip day 1 | 0 ± 0 |
| Right hand pinch grip day 113 | -7.55 ± 26.792 |
| Right hand pinch grip day 169 | -9.35 ± 30.942 |
| Right hand pinch grip day 365 | 0.59 ± 32.094 |
| Right hand pinch grip day 533 | -8.65 ± 21.491 |
| Right hand pinch grip day 729 | -35.40 ± 44.820 |
The effect of BYM338 on additional muscle function measures (6 minute walking distance). The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.
| Meters | BYM338 |
|---|---|
| Day 1 | 0 ± 0 |
| Day 113 | -1.56 ± 13.685 |
| Day 169 | -7.41 ± 12.463 |
| Day 365 | -8.97 ± 15.763 |
| Day 533 | -16.99 ± 22.382 |
| Day 729 | -17.86 ± NA |
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was equal or more than 2% at Week 8 and 16 were considered responders
| Percentage Change | BYM338 |
|---|---|
| Day 1 | 0 ± 0 |
| Day 57 | 4.14 ± 4.250 |
| Day 113 | 4.51 ± 6.300 |
To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1.
| ug/mL | BYM338 |
|---|---|
| Pharmacokinetics (PK) Parameter of Cmax | 278 ± 62.6 |
The time to reach the maximum concentration after drug administration
| hr | BYM338 |
|---|---|
| Time to Reach the Maximum Concentration After Drug Administration (Tmax) | 0.744 ± NA |
Collected over period up to 104 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338 10mg/kg i.v. | — | 2/10 (20%) | 10/10 (100%) |
| Event | BYM338 10mg/kg i.v. |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/10 |
| Myocardial infarctionCardiac disorders | 1/10 |
| TachyarrhythmiaCardiac disorders | 1/10 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/10 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/10 |
| DehydrationMetabolism and nutrition disorders | 1/10 |
| Iron deficiencyMetabolism and nutrition disorders | 1/10 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Event | BYM338 10mg/kg i.v. |
|---|---|
| FallInjury, poisoning and procedural complications | 9/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 9/10 |
| DiarrhoeaGastrointestinal disorders | 6/10 |
| Skin abrasionInjury, poisoning and procedural complications | 5/10 |
| AcneSkin and subcutaneous tissue disorders | 5/10 |
| Oedema peripheralGeneral disorders | 3/10 |
| Urinary tract infectionInfections and infestations | 3/10 |
| Ligament sprainInjury, poisoning and procedural complications | 3/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/10 |
| RashSkin and subcutaneous tissue disorders | 3/10 |
| Age, Continuous(Years) | BYM338 |
|---|---|
| Mean | 70.1 ± 10.39 |
| Sex: Female, Male(Participants) | BYM338 |
|---|---|
| Female | 4 |
| Male | 6 |
Ran from Mar 2014 to primary completion in Aug 2016, 29 months.
Results were first posted in Apr 2018, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab